3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
77
Multiple Myeloma
40
Lymphoma, Large B-Cell, Diffuse
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
37
Lymphoma
37
Lymphoma, Non-Hodgkin
27
Leukemia
26
Leukemia, Lymphocytic, Chronic, B-Cell
18
Burkitt Lymphoma
18
Recurrence
17
Lymphoma, Mantle-Cell
17
Lymphoma, Follicular
17
Neoplasms, Plasma Cell
16
Lymphoma, B-Cell
16
Leukemia, Myeloid, Acute
16
Neuroblastoma
12
Hodgkin Disease
12
Lymphoma, Large-Cell, Immunoblastic
11
Myelodysplastic Syndromes
9
Lymphoma, T-Cell, Peripheral
9
Lymphoma, B-Cell, Marginal Zone
9
Inflammatory Breast Neoplasms
9
Triple Negative Breast Neoplasms
8
Sarcoma
8
Ovarian Neoplasms
8
Immunoblastic Lymphadenopathy
7
Neoplasm Metastasis
6
Melanoma
6
Leukemia, Myeloid, Chronic-Phase
6
Hematologic Neoplasms
6
Interventions
Fulvestrant
5
Letrozole
4
Capecitabine
3
pyrotinib
2
Paclitaxel
2
Goserelin
2
Anastrozole
2
palbociclib
1
olaparib
1
neratinib
1
liposomal doxorubicin
1
exemestane
1
entinostat
1
ceralasertib
1
capivasertib
1
Vinorelbine
1
Trastuzumab
1
Standard of Care
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Injections
1
In Situ Hybridization, Fluorescence
1
Immunotherapy, Adoptive
1
Gonadotropin-Releasing Hormone
1
FCN-437c
1
Docetaxel
1
Decitabine
1
Cyclophosphamide
1
Combined Modality Therapy
1
Cisplatin
1
CYH33
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Advanced Breast Cancer
×
Cyclophosphamide
×
Clear all
NCT04304352
2023-06-28
VEX
European Institute of Oncology
Phase 2
Unknown
162 enrolled